As AIM specialists we are delighted to announce that Dr Jan Groen has joined our client ANGLE plc, a world-leading liquid biopsy company, as Non-Executive Director effective 1 November 2018.
Dr Groen has extensive Board and Executive level experience in cancer diagnostics. He is currently President and CEO of MDxHealth, a Euronext listed molecular diagnostic company that develops and commercialises cancer diagnostic tests to assist physicians in the detection and treatment of urological and other cancers, a position he has held since 2010. During his time at MDxHealth, he has helped to grow revenues from c. US$4 million in 2012 to c. US$41 million in 2017, with a total cumulative revenue of over US$100 million by 2017, and raised US$80 million in equity financing. He has established a CLIA service laboratory in the United States, an ISO service laboratory in Europe and built a team of over 220 staff to sell and undertake their prostate and other cancer diagnostic tests.
Prior to MDx Health, Dr Groen was President of US Operations and Global Chief Operating Officer at Agendia, a world leader in the rapidly evolving field of cancer molecular diagnostics using tumor gene expression, including tests that predict the risk of breast cancer recurrence (MammaPrint) and to identify the origin of cancer of unknown primary.
Dr Groen has significant expertise in new product development, including development of more than 25 CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA, and has successfully launched and commercialised several such tests.
Dr Groen also holds a Non-Executive Board position at SPL Medical, a private Dutch company combining an innovative contrast agent (Combidex®) with magnetic resonance imaging (MRI), with the ability to detect small lymph node metastases. He was previously a board member of MyCartis, a private Belgium company developing a Dynamic Multi-Analyte Technology (DMAT®) for immuno-diagnostics and IBL International, a VC backed company based in Germany manufacturing and selling immune-diagnostic assay which was sold to Tecan in July 2014.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"I am delighted to welcome Jan Groen to the Board of ANGLE. He has a proven track record of successfully commercialising cancer diagnostics in the USA and Europe. His knowledge and experience of this market will be of significant value as we progress the commercialisation of our ParsortixTM liquid biopsy solution."
